2012 11 32 11 CJITWM November 2012 Vol. 32 No. 11 1483 acute coronary syndrome ACS percutaneous coronary intervention PCI 60 ACS 30 30 PCI ACS PCI thrombolysis in myocardial infarction TIMI 3 16 /30 vs 11 /30 P < 0. 01 TIMI 3 14 /14 vs 13 /19 P < 0. 05 TIMI 0 ~ 1 5 /6 vs 3 /13 P < 0. 05 8 /30 vs 15 /30 P < 0. ACS Effects of Suxiao Jiuxin Pill on Patients with Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention WANG Xiao-long LIU Yong-ming ZHU Gu-jing et al Department of Cardiology Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203 ABSTRACT Objective To investigate the intervention effects of Suxiao Jiuxin Pill SJP on patients with a- cute coronary syndrome ACS undergoing early percutaneous coronary intervention PCI. Methods Sixty ACS patients were randomly assigned to the treatment group treated by SJP and Western medicine and the control group treated by Western medicine alone 30 in each group. Coronary arteriography and early PCI were performed in all patients. The effects of SJP on the blood flow rate the collateral artery patency and perioperative myocardial infarction incidence were observed. Results The coronary blood flow rate was better in the treatment group than in the control group either pre- or post-pci. pre-pci thrombolysis in myocardial infarction TIMI level Ⅲ 16 /30 vs 11 /30 P < 0. 01 post-pci TIMI level Ⅲ 14 /14 vs 13 /19 P < 0. 05. In patients with ITMI level 0 - Ⅰ more patients in the treatment group had collateral artery protective function than those in the control group 5 /6 vs 3 /13 P < 0. 05. The incidence of perioperative myocardial infarction was obviously lower in the treatment group than in the control group 8 /30 vs 15 /30 P < 0. 05. Conclusion SJP could improve the pre- and post-pci coronary artery flow rate increase the collateral artery patency and reduce the incidence of perioperative myocardial infarction of ACS patients. KEYWORDS Suxiao Jiuxin Pill acute coronary syndrome coronary artery angiography percutaneous coronary intervention collateral artery circulation perioperative myocardial infarction acute coronary syndrome ACS percutaneous coronary intervention PCI 1 No. 20114049 No. C10dz2220200 201203 Tel 13801802245 E-mail guowei70@ 163. com 2 percutaneous
1484 2012 11 32 11 CJITWM November 2012 Vol. 32 No. 11 transluminal coronary angioplasty PTCA 30 2 1-3 3 P > 0. 05 ACS PCI 1 ACS ACS 1 1. 1 ACS 2007 4 mmol /L 2010 5 2007 6 2010 7 1. 2 8 2002 2 1 2 / 3 3 1 1 2 2. 1 ACS 30 ~ 85 PCI 2. 2 mm / mm 30 30 atm x ± s 11. 9 ± 2. 3 10. 0 ± 2. 7 0. 500 s x ± s 7. 4 ± 3. 2 6. 7 ± 3. 0 0. 637 4 3 BJ06410 300 mg - 2011 11 2012 4 1A660 300 mg PCI P x ± s 65 ± 11 62 ± 12 0. 253 % 22 73. 3 21 70. 0 0. 776 % 6 20. 0 5 16. 7 0. 741 % 17 56. 7 19 63. 3 0. 601 % 17 56. 7 20 66. 7 0. 430 % 4 13. 3 3 10. 0 0. 690 mmol /L x ± s 4. 6 ± 0. 9 4. 2 ± 0. 9 0. 194 x ± s 1. 7 ± 1. 0 1. 5 ± 0. 8 0. 313 mmol /L x ± s 2. 9 ± 0. 7 2. 7 ± 0. 8 0. 287 mmol /L x ± s 1. 0 ± 0. 2 1. 0 ± 0. 2 0. 570 μmol /L x ± s 75. 2 ± 22. 5 82. 8 ± 17. 2 0. 197 mmol /L x ± s 6. 3 ± 2. 8 6. 7 ± 3. 0 0. 597 mmol /L x ± s 340. 9 ± 130. 2 338. 1 ± 115. 6 0. 934 U /L x ± s 38. 5 ± 25. 7 38. 5 ± 24. 8 0. 896 % 16 53. 3 15 50. 0 0. 796 % 12 40. 0 13 43. 3 0. 793 % 2 6. 7 2 6. 7 1. 000 ACS % 30 30 P 30 100. 0 30 100. 0 1. 000 30 100. 0 30 100. 0 1. 000 β- 28 93. 3 27 90. 0 0. 643 22 73. 3 Ⅱ 21 70. 0 0. 776 28 93. 3 28 93. 3 1. 000 ACS 30 30 P % 21 70. 0 17 56. 7 0. 288 % 10 33. 3 14 46. 7 0. 282 % 10 33. 3 10 33. 3 1. 000 B2 /C % 19 63. 3 17 56. 7 0. 601 % 9 30. 0 8 26. 7 0. 776 % 5 16. 7 6 20. 0 0. 741 x ± s 1. 4 ± 0. 7 1. 4 ± 0. 6 0. 845 x ± s 2. 9 ± 0. 4 3. 0 ± 0. 5 0. 544 x ± s 31. 8 ± 18. 9 31. 5 ± 22. 9 0. 814 % 29 96. 7 30 100. 0 0. 317 % 1 3. 3 0 0. 317 60 PCI 60 100 mg
2012 11 32 11 CJITWM November 2012 Vol. 32 No. 11 1485 75 mg 1137069 20 mg creatine kinase isomer-mb CKMB β- 1202063 angiotensin converting enzyme inhibitor ACEI Troponin1 TnI C- 202353 Ⅱ Angiotensin Ⅱ receptor antagonists ARB 110749 2 h 5. 6 PCI 40 mg TnI CKMB 611254 15 15 1 3 99% 1 PCI 10 PCI 5 5. 1 3 11 - AL- 13 LURA XPER FD10 JUDKINS 5 3 9 3 1 7 SPSS 10. 0 1 ~ 2 PCI x ± s t < 30% 9 U χ 2 5. 2 thrombolysis in myocardial infarction TIMI 0 TIMI 1 TIMI 2 TIMI TIMI3 16 /30 vs 11 /30 χ 2 TIMI 3 P < 0. 01 9 5. 3 Rentrop 9 C-reactive protein CRP 3 TnI CKMB 99% PCI 6 P < 0. 05 0 14 TIMI 0 ~ 2 Ⅰ Ⅱ 3 19 TIMI 0 ~ Ⅲ 2 13 3 6 TIMI 5. 4 PCI 2 TIMI 8 24 h 30 3 ml PCI TIMI 0 ~ 2 3 14 / 20 min - 80 14 vs 13 /19 χ 2 P < creatine kinase CK 0. 05 1 PCI 4 PCI TIMI 3 4 ACS PCI % TIMI3 TIMI2 TIMI0 ~ 1 TIMI3 TIMI2 TIMI0 ~ 1 30 16 53. 3 8 26. 7 6 20. 0 30 100. 0 0 0 30 11 36. 7 ** 6 20. 0 13 43. 3 24 80. 0 * 6 20. 0 0 P < 0. 05 P < 0. 01
1486 2012 11 32 11 CJITWM November 2012 Vol. 32 No. 11 2 PCI PCI TIMI 0 ~ 1 ACS 5 /6 vs 3 /13 P < 0. 05 4 PCI CRP 5 8 h 24 h CRP P > 0. 05 5 ACS PCI CRP mg /L x ± s 8 h 24 h 30 13. 0 ± 25. 9 16. 6 ± 28. 0 11. 6 ± 13. 8 30 16. 3 ± 25. 0 25. 5 ± 36. 4 17. 3 ± 27. 3 P 0. 627 0. 299 0. 316 ACS ACS 5 Atorvas- 3 tatin for Reduction of Myocardial Damage during Angioplasty trial ARMYDA ACS ACS 8 PCI 20 30 1 15 8 /30 vs 15 /30 χ 2 ARMYDA-ACS PCI 1 15 P < 0. 05 20 ACS PCI CRP ACS PCI ACS PCI ACS 40% 14-17 PCI PCI 14-18 17 1 Patti G Pasceri V Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary ACS PCI ACS syndromes undergoing early percutaneous coronary intervention results of the ARMYDA-ACS randomized trial J. J Am Coll Cardiol 2007 49 12 1272-1278. TIMI 3 2. J. 2006 25 5 25-26. TIMI 0 ~ 1 3. PTCA J. 2006 37 2 6-8. 4. ACS 36% 19. ST J. 2007 35 4 295-304. 5. 2010
2012 11 32 11 CJITWM November 2012 Vol. 32 No. 11 1487 10 Thygesen K Alpert JS White HD et al. Universal definition of myocardial infarction J. Circulation 2007 116 22 2634-2653. 11 Pasceri V Patti G Nusca A et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention results from the ARMYDA Atorvastatin for Reduction of Myocardial Damage during Angioplasty study J. Circulation 2004 110 6 674-678. 12 Alpert JS Thygesen K Antman E et al. Myocardial infarction redefined a consensus document of The Joint European Society of Cardiology / American College of Cardiology Committee for the Redefinition of Myocardial Infarction J. J Am Coll Cardiol 2000 36 3 959-969. 13 Fox KA Poole-Wilson PA Henderson RA et al. Interventional versus conservative treatment for patients with un- J. 2011 19 8 701-705. stable angina or non-st-elevation myocardial infarction the 6. 2007 British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina J. Lancet J. 2007 35 5 169-172. 2002 360 9336 743-751. 7. 2010 14 Klein LW Kramer BL Howard E et al. Incidence and M. clinical significance of transient creatine kinase elevations 2010 5. and the diagnosis of non-q wave myocardial infarction asso- 8. J. ciated with coronary angioplasty J. J Am Coll Cardiol 1991 11 5 257-258. 1991 17 3 621-626. 9. M. 15 Abdelmeguid AE Topol EJ Whitlow PL et al. Significance of mild transient release of creatine kinase-mb 2001 101-102 124. fraction after percutaneous coronary interventions J. Circulation 1996 94 7 1528-1536. 16 Brener SJ Ellis SG Schneider J et al. Frequency and long-term impact of myonecrosis after coronary stenting J. Eur Heart J 2002 23 11 869-876. 17 Nallamothu BK Bates ER. Periprocedural myocardial infarction and mortality causality versus association J. J Am Coll Cardiol 2003 42 6 1412-1414. 18 Ioannidis JP Karvouni E Katritis DG. Mortality risk conferred by small elevations of creatine kinase-mb isoenzyme after percutaneous coronary intervention J. J Am Coll Cardiol 2003 42 6 1406-1411. 19 Schaper W. Collateral vessels reduce mortality J. Eur Heart J 2012 33 5 564-566. 2012-06 - 13 2012-08 - 15 檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴 2012 2012 2012 8 10 2012 77 7 3 檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴檴